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Abstract: A solid phase extraction-HPLC method has been developed and vali-
dated for the rapid analysis of carbamazepine and its two metabolites, carba-
mazepine epoxide and carbamazepine trans-diol, in human plasma. The anal-
ysis was performed using a C18 Bakerbond-BDC analytical column (250 
mm×4.6 mm i.d., particle size 5 μm). The optimal conditions for the separation 
were established with the mobile phase acetonitrile – 10 mM phosphate buffer, 
pH 7.0 (30:70, v/v) at a flow rate of 1.5 mL min-1 and temperature of 35 °C, 
with UV detection at 210 nm. The total run time was about 8 minutes. The SPE 
procedure for the extraction of the analytes from a plasma sample was deve-
loped using Oasis HLB cartridges and subsequently, the eluate was injected 
into the HPLC system for analysis. Afterwards, the SPE-HPLC method was 
subjected to validation. Linearity was obtained over the concentration range of 
0.2–25 μg mL-1 for carbamazepine, carbamazepine epoxide and carbamazepine 
trans-diol, with correlation coefficients higher than 0.995. The method showed 
good intra-day and inter-day precision with a relative standard deviation below 
7.96 %, while the accuracy ranged from 92.09 to 108.5 % for all analytes. 
Finally, the method was successfully applied to the analysis of the plasma 
samples of epileptic patients in mono- and polytherapy. 
Keywords: human plasma; carbamazepine; carbamazepine epoxide; carbama-
zepine trans-diol; solid phase extraction. 
                                                                                                                    
* Corresponding author. E-mail: pdzodic@gmail.com 
doi: 10.2298/JSC120106084D 
_______________________________________________________________________________________________________________________
2012 Copyright (CC) SCS
Available online at www.shd.org.rs/JSCS/
1424 DŽODIĆ et al. 
INTRODUCTION 
Carbamazepine (CBZ, Fig. 1a) is a tricyclic lipophilic compound used in the 
treatment of epilepsy, trigeminal neuralgia and bipolar disorders.1–3 A CBZ 
plasma concentration ranging from 4 to 12 μg mL–1 is associated with seizure 
control.4,5 CBZ is a strong inducer of microsomal enzymes (cytochrome P450 in 
liver) which can quicken its own metabolism and those of co-administered 
drugs.5 Hence, polytherapy may be associated with drug interactions and unde-
sired toxicity. 
      
      
Fig. 1. Structures of carbamazepine, CBZ (a), carbamazepine epoxide, CBZ-E (b), car-
bamazepine trans-diol, CBZ-DIOH (c) and the internal standard phenobarbital (d). 
Carbamazepine epoxide (CBZ-E, Fig. 1b) is the most important among its 33 
metabolites, because CBZ-E exerts pharmacological activity as does its parent 
compound.6 Afterwards, CBZ-E is mainly metabolized by epoxide hydrolases to 
carbamazepine trans-diol (CBZ-DIOH, Fig. 1c). CBZ-DIOH is fairly conjugated 
with glucuronic acid and excreted in urine.7 Therefore, regular measurement of 
the plasma levels of CBZ and its metabolites and dosage adjustment are neces-
sary for patients undergoing chronic treatment with CBZ. 
Commercially immunoassays are available for the determination of the con-
centration of CBZ. However, CBZ-E cannot be routinely monitored using immu-
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noassays and therefore measurement of both CBZ and CBZ-E requires chroma-
tographic analysis.8 
According to a literature survey, HPLC and HPLC-MS methods have been 
published for the quantitative analysis of CBZ, its metabolites and other medi-
cations in human plasma. The HPLC-MS techniques are not widely used because 
the required expensive equipment is not available in most clinical laboratories. 
Prior to HPLC analysis, human plasma samples were subjected to protein preci-
pitation, liquid–liquid extraction9–15, stir bar-sorptive extraction16 or solid phase 
extraction (SPE).7,17–21 Unfortunately, these methods7,17–21 are time-consuming 
on account of eluate evaporation and subsequent reconstitution in comparison 
with the SPE-HPLC method proposed herein. After the employed SPE proce-
dure, the eluate is injected into the HPLC system without performing evaporation 
and reconstitution steps. Since the total time for sample preparation is shorter 
than 10 min, the proposed SPE-HPLC method is advantageous over the previ-
ously published SPE-HPLC methods7,17–21 in routine application. 
An automated and sensitive SPE-HPLC method for analysis of CBZ, CBZ-E 
and CBZ-DIOH was found. This method was applied to the analysis of plasma 
samples obtained from rats treated with CBZ,22 but the applicability of the me-
thod to samples obtained from epileptic patients was not examined. According to 
the chromatogram of spiked drug-free plasma, interfering substances from human 
plasma were not completely separated from peaks of the analytes and internal 
standard.22 Considering the proposed SPE-HPLC method, the total chromate-
graphic run time was about 8 min with excellent peak shapes and good resolution 
between the investigated compounds and interfering plasma substances. Further-
more, expenses and the overall time of therapeutic drug monitoring are reduced, 
which is important in the individualization of therapy of patients undergoing 
chronic treatment with CBZ. 
SPE-HPLC method was subjected to validation according to US Food and 
Drug Administration (FDA)23 and International Conference on Harmonisation 
(ICH)24 guidelines. It fulfills the validation criteria in every segment of vali-
dation. Finally, the developed method was successfully applied to routine anal-
ysis of plasma samples of epileptic patients under both mono- and polytherapy. It 
could be used for cost-effective therapeutic drug monitoring of CBZ due to its 
appropriate sensitivity and selectivity. 
EXPERIMENTAL 
Chemicals and reagents 
CBZ and internal standard phenobarbital (IS, Fig. 1d) as solid standard compounds were 
kindly provided by pharmaceutical company Galenika (Belgrade, Serbia). CBZ-E and CBZ- 
-DIOH as solid standard compounds were kindly provided by pharmaceutical company 
Novartis Pharma (Basel, Switzerland). Acetonitrile and methanol HPLC gradient grade were 
purchased from Avantor Performance Materials (Deventer, The Netherlands). Sodium hydro-
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xide and sodium dihydrogen phosphate suitable for HPLC were obtained from Merck (Darm-
stadt, Germany). 
Instrumentation and materials 
HPLC analysis was performed with an Agilent Technologies 1200 (Wilmington, DE, 
USA) chromatographic system equipped with on-line degasser, binary pump, column oven 
and photo diode array detector. Sample injection of 10 μL was performed using an Agilent 
1200 Series high performance autosampler G1367B. Water for chromatography was obtained 
from a Smart 2 Pure (TKA, Niederelbert, Germany) purification system. Before use, the mo-
bile phase was degassed and purified by vacuum filtration through 0.45 μm regenerated cel-
lulose membrane filters (Agilent, Böblingen, Germany). The compounds were separated on a 
C18 Bakerbond-BDC analytical column (250 mm×4.6 mm; 5 μm) (Avantor performance 
materials, Deventer, The Netherlands). Data were acquired with Agilent ChemStation soft-
ware. Statistical analysis was performed using Microsoft Excel software. 
The SPE procedure was performed using a Visiprep-DL Vacuum Manifold, 12-port 
model from Supelco (Bellefonte, USA) coupled to a vacuum pump from KNF Neuberger 
(Freiburg, Germany). Oasis HLB cartridges (30 mg, 1 mL, particle size 30 μm) were pur-
chased from Waters (Milford, MA, USA). 
Chromatographic conditions 
The mobile phase was 30:70 (v/v) acetonitrile–10 mM sodium dihydrogen phosphate 
(pH 7.0 adjusted with 1 M sodium hydroxide). The flow rate was 1.5 mL min-1 and the co-
lumn temperature was set at 35 °C. Detection was performed at 210 nm. 
Human plasma samples 
Patients and healthy volunteers who donated plasma samples gave written informed 
consent, and all investigations were approved by the Ethical committee (Faculty of Medicine, 
University of Niš, Serbia). Blank plasma was obtained from ten different healthy volunteers. 
Plasma samples from patients were obtained from Clinic of Neurology (University Clinical 
Centre Niš, Serbia). Blood samples were collected into vacutainers containing EDTA-Na, and 
separated by centrifugation at 3000 g for 10 min. All samples were stored at –80 °C before 
analysis. 
Standard solutions, calibration standards and quality control samples 
Four standard stock solutions of CBZ, CBZ-E, CBZ-DIOH and IS were prepared in 
acetonitrile at a concentration of 10 mg mL-1. The standard working solutions of CBZ, CBZ-E, 
CBZ-DIOH and IS contained 1 mg mL-1 in the mobile phase. Standard stock solutions were 
stored at –20°C and standard working solutions were stored at 4–8 °C for 1 month. No 
stability related problems were encountered during this period. 
Each analyte was added separately for the preparation of standard curve samples. Vo-
lumes of 0.1, 0.3, 2.5, 5, 7.5, 10 and 12.5 μL of 1 mg mL-1 CBZ, CBZ-E and CBZ-DIOH 
standard working solutions were transferred to seven Eppendorf tubes containing 0.5 mL of 
blank human plasma. Five μL of 1 mg mL-1 IS standard working solution was added to each 
of the Eppendorf tubes. After dilution and the SPE procedure 0.2, 0.6, 5, 10, 15, 20 and 25 μg 
mL-1 of CBZ, CBZ-E and CBZ-DIOH were obtained in the eluates. Concentration of IS was 
10 μg mL-1. The zero plasma samples were prepared by adding IS to drug-free human plasma 
to yield a final concentration of 10 μg mL-1. 
The quality control (QC) plasma samples were prepared to final concentrations of 0.6 
(low), 10 (medium) and 20 μg mL-1 (high) of all the investigated compounds. The concentra-
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tion of IS was 10 μg mL-1. QC (medium) samples were used for the optimization of the SPE 
procedure. 
QC samples were prepared daily, and parts of the low and high QC samples were stored 
at –80 °C to study their stability after three freeze–thaw cycles and long-term stability. 
Solid phase extraction procedure 
Phosphate buffer (10 mM of sodium dihydrogen phosphate, pH 7.0) was added to the 
prepared samples (calibration standards, QC samples) to a volume of 1 mL, which was fol-
lowed by brief vortex mixing. 
The flow rate during the SPE procedure was maintained at about 1.0 mL min-1. The SPE 
cartridges were conditioned with 1 mL of methanol, and 1 ml of the phosphate buffer (10 
mM; pH 7.0). The diluted plasma samples (1 mL) were loaded onto the cartridges. A wash 
step was performed with 1 mL of phosphate buffer (10 mM; pH 7.0) and subsequently 1 mL 
of methanol – 10 mM phosphate buffer, pH 7.0 (20:80, v/v). The cartridges were then dried 
under vacuum (–40 kPa) for 30 s. Finally, the analytes and IS were eluted with 0.5 mL of 
acetonitrile – 10 mM phosphate buffer, pH 7.0 (60:40, v/v). A 10 μL volume of the eluate was 
injected into the HPLC system for analysis. 
RESULTS AND DISCUSSION 
Development of the HPLC method 
At the beginning of the investigation, log D values of the compounds were 
calculated using MarvinSketch software.25 The log D values of CBZ-DIOH, CBZ-E 
and CBZ were 0.81, 1.97 and 2.77, respectively (Table I). The log D values were 
pH independent except for CBZ-DIOH, the ionic form of which appeared at pH 
values higher than 9.80. Therefore, the log D values of CBZ-DIOH, CBZ-E and 
CBZ are equivalent to their log P values at pH values lower than 9.80. Due to the 
lipophilic nature of CBZ-E and CBZ, a C18 column package was chosen. The 
following columns were investigated: Bakerbond-BDC C18 (150 mm×4.6 mm; 5 
μm), Bakerbond-BDC C18 (250 mm×4.6 mm; 5 μm) and Symmetry C18 (150 
mm×4.6 mm; 5 μm). The Bakerbond-BDC C18 analytical columns are better 
than the classical C18 columns owing to improved peak symmetry, lower back 
pressure and a longer column lifetime. By using Bakerbond-BDC C18 (150 
mm×4.6 mm; 5µm) it was not possible to adequately separate the interfering 
plasma compounds from the analytes (CBZ, CBZ-E and CBZ-DIOH). Therefore, 
a longer column Bakerbond-BDC C18 (250 mm×4.6 mm; 5µm) was used. As a 
result, the analytes were successfully separated from the plasma compounds. 
TABLE I. pKa and log D values of the investigated compounds 
Parameter CBZ-DIOH CBZ-E CBZ 
log D 0.81 1.97 2.77 
pKa 12.80 – – 
When methanol was a constituent of a mobile phase, peak symmetry and re-
solution between the contiguous analytes were poor. Considering the absorption of 
methanol at 210 nm, acetonitrile was examined as a constituent of the mobile phase. 
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CBZ and CBZ-E are neutral analytes, and CBZ-DIOH is a weak acid (pKa =  
= 12.80). The examined pH range during the development of a chromatographic 
method is usually lower than 11. Therefore, it could be concluded that the pH of 
the mobile phase would not influence the retention of the investigated com-
pounds, which was confirmed by a few experiments (mixtures 30:70 (v/v) aceto-
nitrile−the phosphate buffer (10 mM) were used with a flow rate of 1.5 mL min–1 
and column temperature at 35 °C with the pH adjusted to 6.2, 7 and 8.2). Further-
more, it was decided to use a mobile phase with the pH adjusted to 7. This deci-
sion was based on the chromatographic behavior of IS in order to shorten its re-
tention time and hence the total run time.  
Three variables were left to be optimized: percentage of acetonitrile, flow 
rate and temperature of the column. Firstly, a mixture 40:60 (v/v) acetonit-
rile−water was used as the mobile phase at a flow rate of 1 mL min–1 and with 
the column temperature at 30 °C. Under these chromatographic conditions, very 
poor retention of CBZ-DIOH was achieved. Afterwards, the percentage of water 
was increased and a mixture 35:65 (v/v) acetonitrile−water was used as the mo-
bile phase, while the other chromatographic conditions remained the same. The 
retention factor of CBZ-DIOH was 0.37, although it was noticed that the de-
crease in the percentage of acetonitrile led to an increase in the retention factors 
of all the investigated compounds. Subsequently, a mixture 35:65 (v/v) acetonit-
rile− phosphate buffer (10 mM; pH 7.0) was used as the mobile phase at a flow 
rate of 1 mL min–1 and a column temperature of 30 °C. Addition of the phos-
phate buffer resulted in a better symmetry of the analyte peaks. Although the cri-
tical resolution of IS and CBZ-E peaks was improved, the retention factor of 
CBZ-DIOH was still less than 1. Therefore, the percentage of acetonitrile in mo-
bile phase was decreased again and a mixture 30:70 (v/v) acetonitrile− phosphate 
buffer (10 mM; pH 7.0) was used at a flow rate of 1 mL min–1 and column tem-
perature at 30 °C. Now the separation was successful and retention factor of 
CBZ-DIOH was 0.98, but chromatographic run lasted about 12 minutes. Hence, 
the flow rate was increased to 1.5 mL min–1 and the column temperature was 
increased to 35 °C. As a result, the total chromatographic run was shortened to 
about 8 min. Excellent peak shapes, good resolution between the contiguous 
peaks, and a number of theoretical plates of more than 17000 for all peaks were 
achieved. Retention factor of CBZ-DIOH was 1.02. Thus, these chromatographic 
conditions were chosen. 
Development of the SPE procedure for sample pretreatment 
Due to the different polarity of the neutral analytes (CBZ, CBZ-E and CBZ- 
-DIOH), Oasis HLB cartridges were chosen since the polymeric sorbent retains 
both polar and non-polar compounds.26 
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As the analytes are neutral compounds and it was proven during develop-
ment of the HPLC method that pH had no influence on the retention of the ana-
lytes, it was decided to use the buffer which was a constituent of the mobile 
phase (10 mM sodium dihydrogen phosphate, pH 7.0) for the conditioning of the 
cartridges, as well as for the wash and the elution steps. The selectivity was en-
hanced by tuning the ratio of the organic solvent to the phosphate buffer (10 mM; 
pH 7.0). Absolute recovery values of the investigated compounds were calculated 
for the optimization of the SPE procedure. 
After load step of QC medium samples, the sorbent completely retained the 
analytes and IS. The first wash step was performed by passing 1 mL of the phos-
phate buffer (10 mM; pH 7.0), which did not remove any analyte or IS from the 
cartridge. For the second wash step, 1 mL of the mixtures 5:95, 10:90, 15:85, 
20:80 and 30:70 (v/v) methanol−phosphate buffer (10 mM; pH 7.0) were inves-
tigated. The mixture 20:80 (v/v) methanol−phosphate buffer (10 mM; pH 7.0) 
was the highest percentage of methanol that did not remove any analyte or IS 
from the cartridge. 
For the elution step, 0.5 mL of 30:70, 40:60, 50:50, 60:40 and 70:30 (v/v) 
acetonitrile−phosphate buffer (10 mM; pH 7.0) were investigated. The mixture 
60:40 (v/v) acetonitrile−phosphate buffer (10 mM; pH 7.0) was the lowest per-
centage of acetonitrile which completely eluted the analytes and IS from the car-
tridge. The total time for sample preparation was shorter than 10 min. 
Method validation 
The new SPE-HPLC method was validated following FDA23 and ICH24 
guidelines. The following validation characteristics were evaluated: selectivity, 
sensitivity, linearity, precision, accuracy, absolute recovery and stability. 
The proposed method is selective since co-elution was not spotted at the re-
tention times of CBZ, CBZ-E, CBZ-DIOH and IS from freshly prepared spiked 
samples at LLOQ levels compared to the blank plasma obtained from 10 healthy 
volunteers. The corresponding chromatogram of blank plasma sample is shown 
in Supplementary material to this paper. 
The calibration curves showed good linearity over the investigated concen-
tration range (0.2−25 μg mL–1 for all analytes). The obtained calibration curves 
were: 
 y = 0.1347x − 0.0118; r2 = 0.9964 for CBZ-DIOH (1) 
 y = 0.1749x − 0.0725; r2 = 0.9951 for CBZ-E (2) 
and 
 y = 0.1426x − 0.0436; r2 = 0.9976 for CBZ (3) 
where y is peak area ratio, x is concentration of the compound and r is the corre-
lation coefficient. The intercepts of the calibration curves were tested using the 
student’s t-test. The following results were found for the standard deviation of 
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the slope (Sa), standard deviation of the intercept (Sb) and the confidence factor 
(tα): Sa = 0.0051, Sb = 0.0716 and tα = 0.1642 for CBZ-DIOH; Sa = 0.0078, Sb =  
= 0.1093 and tα = 0.663 for CBZ-E; and Sa = 0.0044, Sb = 0.0615 and tα = 0.7093 
for CBZ. The deviation of the intercepts from zero were found to be insignificant 
(p = 0.05 and ttab = 2.37). The corresponding chromatograms obtained from plasma 
sample spiked with IS, and plasma sample spiked with the analytes and IS in 
Supplementary material to this paper. 
Limit of detection (LOD) and lower limit of quantification (LLOQ) values 
for all compounds were found to be 0.02 μg mL–1 and 0.2 μg mL–1, respectively. 
The accuracy and precision were evaluated in five replicates at the LLOQ level. 
Accuracy is reported as recovery (R in %), precision as relative standard devia-
tion (RSD in %) and the assessed values are given in Table II. 
TABLE II. Intra-day precision and accuracy at LLOQ, low QC, medium QC, and high QC 
concentrations in plasma samples for CBZ-DIOH, CBZ-E and CBZ (n = 5) 
Parameter Nominal concentration in plasma, μg mL
-1 
0.2 0.6 10 20 
CBZ-DIOH 
Precision (RSD / %) 5.42 7.3 7.15 2.89 
Accuracy (R / %) 102.63 92.72 108.50 103.27 
Found concentration, μg mL-1 0.205 0.556 10.85 20.65 
CBZ-E 
Precision (RSD / %) 7.24 6.41 0.97 1.58 
Accuracy (R / %) 114.41 98.60 98.95 98.30 
Found concentration, μg mL-1 0.229 0.592 9.895 19.659 
CBZ 
Precision (RSD / %) 11.24 5.20 1.20 3.41 
Accuracy (R / %) 89.05 102.77 98.71 103.87 
Found concentration, μg mL-1 0.178 0.617 9.87 20.77 
After investigation of the intra-day and inter-day accuracy and precision at 
QC concentration levels, it was found that the obtained results for RSD (%) and 
recovery (R, %) were pursuant to FDA guidance23 (precision of 20 % and accu-
racy of 80–120 % at the LLOQ; and precision of 15 % and accuracy of 85–115 % 
at the low QC, medium QC and high QC levels). The results are listed in Tables 
II and III. 
To evaluate efficiency of the SPE procedure, the absolute recovery values 
were calculated. Spiked drug-free plasma samples at low QC, medium QC and 
high QC levels were diluted to 1 ml with the phosphate buffer and subjected to 
the SPE procedure. These samples were compared to blank plasma that had been 
extracted following the same SPE procedure and then spiked at the same concen-
tration levels. The absolute recovery values as well as the estimated concentra-
tions from human plasma for the investigated compounds are displayed in Table 
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IV. The absolute recovery values of all analytes did not appear to be dependent 
on concentration. 
TABLE III. Inter-day precision and accuracy at LLOQ, low QC, medium QC, and high QC 
concentrations in plasma samples for CBZ-DIOH, CBZ-E and CBZ (n = 5) 
Parameter Nominal concentration in plasma, μg mL
-1 
0.6 10 20 
CBZ-DIOH 
Precision (RSD / %) 7.96 4.11 0.81 
Accuracy (R / %) 92.09 104.58 100.90 
Found concentration, μg mL-1 0.55 10.46 20.18 
CBZ-E 
Precision (RSD / %) 3.99 1.65 3.54 
Accuracy (R / %) 93.34 98.23 104.04 
Found concentration, μg mL-1 0.56 9.82 20.81 
CBZ 
Precision (RSD / %) 1.14 2.16 5.42 
Accuracy (R / %) 98.06 100.00 106.31 
Found concentration, μg mL-1 0.59 10.00 21.26 
TABLE IV. Absolute recoveries of CBZ-DIOH, CBZ-E and CBZ from plasma samples (n = 5) 
Parameter Nominal concentration in plasma, μg mL
-1 
0.6 10 20 
CBZ-DIOH 
Recovery, % 96.51 90.75 100.12 
RSD / % 9.30 5.58 0.81 
Found concentration, μg mL-1 0.579 9.07 20.02 
CBZ-E 
Recovery, % 104.04 95.89 93.80 
RSD / % 3.99 0.97 3.54 
Found concentration, μg mL-1 0.624 9.589 18.76 
CBZ 
Recovery, % 102.18 87.39 94.46 
RSD / % 1.14 1.20 5.42 
Found concentration, μg mL-1 0.613 8.74 18.89 
After performing the stability tests at low QC and high QC levels (short term, 
post-preparative, long-term stability and freeze–thaw cycles), the RSD values for 
the investigated compounds were below 8.39 %, while recovery values ranged from 
90.84 to 112.35 %. Hence, the stability of the analytes was appropriate during all 
investigations. The results of the stability tests are given in Tables V–VIII. 
Clinical application 
Results of the assay of plasma samples obtained from nine epileptic patients 
under chronic treatment with CBZ are listed in Table IX. Along with CBZ, the 
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patients were co-administrated with amlodipine, bromazepam, dihydroergotoxine 
mesylate, aminophylline, fenoterol bromide, ipratropium bromide, beclometha-
sone dipropionate, prednisone, ramipril, losartan, acetylsalicylic acid, α-toco-
pherolacetate, nicergoline, lamotrigine, sodium valproate, topiramate, clonaze-
pam, diazepam, lorazepam, phenytoin and ethosuximide. In all cases, no co-elu-
tion was observed at the retention times of the analytes and IS. To investigate ad-
ditionally the selectivity of the method, plasma samples from healthy volunteers 
who had been administrated with the above-mentioned drugs were assayed and 
no interferences were registered. 
On balance, the applicability of the method to routine analysis of plasma 
samples of epileptic patients under mono- and polytherapy was demonstrated. It 
allows for therapeutic drug monitoring of CBZ. However, the proposed method 
cannot be applied to analysis of plasma samples of patients co-administrated with 
CBZ and Phenobarbital, since it is used as an internal standard. 
TABLE V. Results of short-term stability tests at low QC and high QC concentrations in 
plasma samples (n = 5) 




Recovery, % 99.71 105.49 
RSD / % 2.93 4.44 
Found concentration, μg mL-1 0.598 21.10 
CBZ-E 
Recovery, % 90.84 104.26 
RSD / % 8.39 1.01 
Found concentration, μg mL-1 0.545 20.85 
CBZ 
Recovery, % 91.82 110.22 
RSD / % 3.81 1.43 
Found concentration, μg mL-1 0.551 22.04 
TABLE VI. Results of the post-preparative stability test at low QC and high QC concentra-
tions in plasma samples (n = 5) 




Recovery, % 101.56 99.77 
RSD / % 6.81 0.64 
Found concentration, μg mL-1 0.609 19.95 
CBZ-E 
Recovery, % 96.18 99.82 
RSD / % 5.57 1.28 
Found concentration, μg mL-1 0.577 19.96 
_______________________________________________________________________________________________________________________
2012 Copyright (CC) SCS
Available online at www.shd.org.rs/JSCS/
 SPE-HPLC OF CARBAMAZEPINE AND METABOLITES IN PLASMA 1433 
TABLE VI. Continued 




Recovery, % 96.42 100.66 
RSD / % 5.47 2.52 
Found concentration, μg mL-1 0.579 20.132 
TABLE VII. Results of the freeze–thaw stability test at low QC and high QC concentrations 
in plasma samples (n = 5) 




Recovery, % 112.35 102.66 
RSD / % 2.20 1.36 
Found concentration, μg mL-1 0.674 20.53 
CBZ-E 
Recovery, % 102.40 102.66 
RSD / % 7.29 1.69 
Found concentration, μg mL-1 0.614 20.53 
CBZ 
Recovery, % 105.42 103.63 
RSD / % 2.64 1.22 
Found concentration, μg mL-1 0.63 20.73 
TABLE VIII. Results of the long-term stability test at low QC and high QC concentrations in 
plasma samples (n = 5) 




Recovery, % 110.18 99.71 
RSD / % 2.39 5.96 
Found concentration, μg mL-1 0.661 19.94 
CBZ-E 
Recovery, % 102.31 101.06 
RSD / % 3.60 5.23 
Found concentration, μg mL-1 0.614 20.21 
CBZ 
Recovery, % 109.32 97.09 
RSD / % 2.02 4.39 
Found concentration, μg mL-1 0.656 19.42 
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TABLE IX. Results of the assay of plasma samples obtained from nine epileptic patients 
under treatment with CBZ (n = 5) 
Patient Hours from last dosage CBZ dosage, mg day
-1 (Mean concentrationa ± SDb) / μg mL-1 
CBZ CBZ-E CBZ-DIOH 
S.A 10.5 400 6.47±0.03 1.36±0.06 1.06±0.01 
R.J. 10 600 8.74±0.05 2.06±0.02 3.06±0.04 
M.L. 1 200 4.72±0.03 1.34±0.02 0.88±0.03 
I.I. 9 400 7.12±0.07 1.44±0.03 1.40±0.06 
A.D. 12 600 11.95±0.12 2.24±0.08 4.53±0.07 
B.V. 13 1200 16.91±0.11 3.99±0.05 6.84±0.06 
I.S 4 600 5.43±0.05 1.48±0.03 1.75±0.03 
P.B. 3 400 8.7±0.07 1.69±0.04 1.48±0.09 
T.R. 10.5 600 NDc ND ND 
aMean concentration in plasma, μg mL-1; bstandard deviation, μg mL-1; cnot determined, concentration was 
below the LLOQ 
CONCLUSIONS 
The chromatographic behavior of the investigated compounds was exa-
mined. As a result, an SPE-HPLC method was developed and validated. It showed 
satisfactory precision and accuracy with RSD values in the range from 0.81 to 
11.24 % and recovery (R, %) values from 89.05 to 114.41 %. The linearity of the 
method was adequate in the range 0.20−25 µg mL–1 with a correlation coeffi-
cient higher than 0.9951 for the investigated compounds. The efficiency of the 
extraction procedure was established with the assistance of absolute recovery 
values, which were calculated to be from 87.39 to 104.04 %. During analysis of 
plasma samples obtained from patients, no interferences from endogenous com-
pounds and co-administered drugs were found. Therefore, the developed chroma-
tographic method was shown to be suitable for the simultaneous determination of 
CBZ and its metabolites CBZ-E and CBZ-DIOH in the plasma of epileptic pa-
tients. The short chromatographic run time and the rapid SPE procedure are im-
portant advantages of the proposed SPE-HPLC method for its routine appli-
cation. In conclusion, the applicability of the method to therapeutic drug moni-
toring of patients under chronic treatment with CBZ was proved. 
SUPPLEMENTARY MATERIAL 
Representative chromatograms of blank plasma, blank plasma spiked with internal 
standard, blank plasma spiked with CBZ, CBZ-E, CBZ-DIOH and internal standard and 
plasma sample of an epileptic patient after receiving an oral dose of CBZ are available elec-
tronically from http://www.shd.org.rs/JSCS/, or from the corresponding author on request. 
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И З В О Д  
РАЗВОЈ И ВАЛИДАЦИЈА SPE-HPLC МЕТОДЕ ЗА ОДРЕЂИВАЊЕ КАРБАМАЗЕПИНА И 
МЕТАБОЛИТА КАРБАМАЗЕПИН ЕПОКСИДА И КАРБАМАЗЕПИН 
trans-ДИОЛА У ПЛАЗМИ 
ПРЕДРАГ ЏОДИЋ1, ЉИЉАНА ЖИВАНОВИЋ2, АНА ПРОТИЋ2, ИВАНА ИВАНОВИЋ3, 
РАДМИЛА ВЕЛИЧКОВИЋ-РАДОВАНОВИЋ1, МИРЈАНА СПАСИЋ1, СТЕВО ЛУКИЋ1 и СЛАВОЉУБ ЖИВАНОВИЋ1 
1Универзитет у Нишу, Медицински факултет, Булевар др Зорана Ђинђића 81, 18000 Ниш, 
2Универзитет у Београду, Фармацеутски факултет, Катедра за аналитику лекова, Војводе Степе 
450, 11221 Београд и 3 Avantor Performance Materials, Teugseweg 20, 7400 AA Deventer, The Netherlands 
SPE-HPLC метода је развијена и валидирана у циљу брзог анализирања карбама-
зепина и метаболита карбамазепин епоксида и карбамазепин trans-диола у хуманој 
плазми. C18 Bakerbond-BDC аналитичка колона (250 mm×4,6 mm; 5 μm) је коришћена 
ради извођења анализе. Оптимални услови за хроматографско раздвајање су мобилна 
фаза ацетонитрил – 10 mM фосфатни пуфер, pH 7,0 (30:70, v/v), проток од 1,5 ml min-1, 
температура 35 °C и детекција на 210 nm. Укупно трајање хроматографског рана износи 
око 8 min. SPE процедура за екстракцију аналита из узорака плазме је развијена уз ко-
ришћење Oasis HLB кетриџа након чега се елуат ињектује у HPLC систем ради анализи-
рања. Затим је извршена валидација SPE-HPLC методе. Линеарност је потврђена у кон-
центрационом опсегу 0,2–25 μg/ml за карбамазепин, карбамазепин епоксид и карбама-
зепин транс-диол са вредношћу корелационих коефицијената вишом од 0,995. Прециз-
ност методе у току једног и у току више дана је добра са релативном стандардном де-
вијацијом нижом од 7,96 %, док тачност методе обухвата вредности у опсегу од 92,09 до 
108,5 % за све аналите. На крају је метода успешно примењена у циљу анализирања 
узорака плазме пацијената оболелих од епилепсије на монотерапији и политерапији. 
(Примљено 6. јануара, ревидирано 11. јуна 2012) 
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